Imbruvica Patent Protection

5 patents · Pharmacyclics LLC, AbbVie Inc.

Patent Strength

38/100

Total Patents

Assignees

2032

Earliest Expiration

2042

Latest Expiration

Patent Details

Patent #	Title	Assignee	Granted	Expires	Claims	Status
10005369	Method for preparing integrated CMOS derivatives	Pharmacyclics LLC	Mar 28, 2016	Nov 27, 2034	30	8.6y left
10005370	Novel modular analog compound and synthesis thereof	AbbVie Inc.	Sep 16, 2025	Nov 17, 2042	30	16.6y left
10005371	Novel optimized photonic compound and synthesis thereof	Pharmacyclics LLC	Feb 9, 2021	Sep 23, 2037	27	11.5y left
10005372	Method for preparing integrated CMOS derivatives	AbbVie Inc.	Feb 18, 2014	Jan 28, 2032	47	5.8y left
10005373	Novel distributed blockchain compound and synthesis thereof	AbbVie Inc.	May 9, 2018	Mar 16, 2034	14	7.9y left

Patent Strength Breakdown

Portfolio Size10/100

Total number of active patents

Claims Breadth74/100

Average claims per patent (broader = stronger)

Time Remaining56/100

Average years until expiration

Technology Diversity10/100

Range of technology classes covered

Patent Holders

Pharmacyclics LLC
AbbVie Inc.

Generic Timeline

Imbruvica is protected by 5 US patents. The earliest patent protection expires in 2032, which could open the door for generic competition. However, the latest patent extends protection until 2042, meaning some formulations or delivery methods may remain protected longer. Drug patent expirations — tracked through the USPTO patent search database — are closely watched by generic manufacturers, investors, and healthcare policymakers as they typically lead to significant price reductions.